Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer
Latest Information Update: 03 Jul 2024
At a glance
- Drugs Cetuximab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms FIRE-3
- 04 Jun 2024 Results of updated evaluation of therapeutic efficacy of targeted therapy with bevacizumab versus cetuximab in RASmut mCRC, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 20 Jan 2024 Results of pooled analysis from TRIBE , FIRE-3 and MAVERICC ; investigating the effect of myostatin/activin pathway gene expression and SNPs in mCRC patients, presented at the 2024 Gastrointestinal Cancers Symposium
- 20 Jan 2024 Results assessing Refining first-line treatment decision in RAS wildtype metastatic colorectal cancer by combining clinical biomarkers presented at the 2024 Gastrointestinal Cancers Symposium